Intravenous amino acids for kidney protection in patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized controlled trials.
Malik Waleed Zeb Khan, Aizaz Ali, Amna Hussain, Aban Masaud Mian, Abdul Moeez, Waqas Inayat, Bushra Noor, Izhar Ali Shah, Muhammad Osama, Bushra Khan, Muhammad Sajid, Touba Azeem, Mohammad Ebad Ur Rehman, Ashraf Ali, Ubaid Khan Afridi
{"title":"Intravenous amino acids for kidney protection in patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized controlled trials.","authors":"Malik Waleed Zeb Khan, Aizaz Ali, Amna Hussain, Aban Masaud Mian, Abdul Moeez, Waqas Inayat, Bushra Noor, Izhar Ali Shah, Muhammad Osama, Bushra Khan, Muhammad Sajid, Touba Azeem, Mohammad Ebad Ur Rehman, Ashraf Ali, Ubaid Khan Afridi","doi":"10.1177/03000605251315919","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of intravenous (IV) amino acids in preventing acute kidney injury (AKI) in patients undergoing cardiac surgery.</p><p><strong>Methods: </strong>PubMed, EMBASE, and Cochrane Library databases were systematically searched for all relevant randomised controlled trials (RCTs) published from inception to July 25, 2024. A random effects model was used to pool the risk ratios (RR) for dichotomous outcomes, and the combined data was visually represented using forest plots.</p><p><strong>Results: </strong>3 studies involving 3646 patients were included in the meta-analysis. IV amino acids did not significantly lower the overall AKI incidence compared with control measures. However, they significantly reduced the risk of Stage 1 AKI and Stage 3 AKI. No differences were observed between intervention and control for Stage 2 AKI or need for kidney replacement therapy.</p><p><strong>Conclusion: </strong>IV amino acids may offer protective benefits against severe AKI stages in cardiac surgery patients. Further studies are warranted to validate our findings.</p>","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":"53 2","pages":"3000605251315919"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792033/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605251315919","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the efficacy of intravenous (IV) amino acids in preventing acute kidney injury (AKI) in patients undergoing cardiac surgery.
Methods: PubMed, EMBASE, and Cochrane Library databases were systematically searched for all relevant randomised controlled trials (RCTs) published from inception to July 25, 2024. A random effects model was used to pool the risk ratios (RR) for dichotomous outcomes, and the combined data was visually represented using forest plots.
Results: 3 studies involving 3646 patients were included in the meta-analysis. IV amino acids did not significantly lower the overall AKI incidence compared with control measures. However, they significantly reduced the risk of Stage 1 AKI and Stage 3 AKI. No differences were observed between intervention and control for Stage 2 AKI or need for kidney replacement therapy.
Conclusion: IV amino acids may offer protective benefits against severe AKI stages in cardiac surgery patients. Further studies are warranted to validate our findings.
期刊介绍：
_Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis.
As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible.
Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence.
Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements.
Print ISSN: 0300-0605
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
